フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial Sub-study will investigate effects of MST-188 on tissue oxygenation in sickle...
Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease MST-188 decreased a marker of inflammation and red blood cell...
Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc. - All-stock transaction - Conference call to discuss pending...
Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10 PR Newswire SAN DIEGO, Sept. 3, 2013...
ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX" PR Newswire SAN DIEGO, March 11, 2013...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX" Name and ticker symbol...
Adventrx To Develop ANX-188 For Complications Of Arterial Disease - Seeking orphan drug designation in acute limb ischemia (ALI) - Phase 2...
ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications - Platform includes over 100 pharmacology studies, 15 clinical studies...
ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4 PR Newswire SAN DIEGO, Feb. 25, 2013 SAN DIEGO, Feb...
ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188 PR Newswire SAN DIEGO, Feb. 11, 2013 SAN DIEGO, Feb. 11, 2013 /PRNewswire/...
ADVENTRX To Present At The 15th Annual BIO CEO & Investor Conference On February 12 /* Style Definitions */ span.prnews_span { font-size:8p...
ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188 /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black;...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約